(Reuters) – Swiss drug maker Actelion’s chief executive quashed speculation over its possible interest in purchasing Basilea Pharmaceutica.
“Basilea has developed interesting medications. But the company already has a partner,” Chief Executive Jean-Paul Clozel was quoted as saying in an interview published on Swiss paper Finanz und Wirtschaft’s website on Friday.
“Since we’re interested in active substances and not financial opportunities, it wouldn’t make sense for us to buy Basilea.”
(Reporting by Brenna Hughes Neghaiwi)
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
